Brief: Protalix Biotherapeutics Reports Third Quarter 2023 Financial And Business Results
06/11/2023 11:52
Nov 6 (Reuters) - Protalix Biotherapeutics Inc PBDA.F :
* PROTALIX BIOTHERAPEUTICS REPORTS THIRD QUARTER 2023
FINANCIAL
AND BUSINESS RESULTS
* PROTALIX BIOTHERAPEUTICS INC - CASH, CASH EQUIVALENTS AND
SHORT
TERM BANK DEPOSITS WERE APPROXIMATELY $41.0 MILLION AT SEPTEMBER
30, 2023.
* PROTALIX BIOTHERAPEUTICS INC - QTRLY LOSS PER SHARE $0.04
* PROTALIX BIOTHERAPEUTICS INC: QTRLY REVENUES $10.2
MILLION, UP
16%
Source text for Eikon: ID:nPn7tfTNwa
Further company coverage: PBDA.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Protalix BioTherapeutics
See all newsIsrael's Protalix Q2 revenue rises on Elfabrio sales, reiterates 2026 outlook
Israel's Protalix Q1 revenue surges on Chiesi milestone
Brief: Protalix BioTherapeutics Q1 EPS USD 0.23
Brief: Protalix Biotherapeutics Reports Fiscal Year 2025 Financial And Business Results
Brief: EU Approves Four‑week Dosing Option For Chiesi and Protalix’s Elfabrio